Skip to main content

Table 4 Descriptive and comparative analysis between the four drugs regarding the percentage of injections made, per patient, in periods of 90 days

From: Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study

Drug

n

(%)

  

Mean ± SD

Median (Q1–Q3)

Aflibercept

33

49.7 ± 1.4

50.0 (50.0–50.0)

Bevacizumab

32

28.1 ± 19.1

33.3 (8.3–50.0)

Ranibizumab

33

26.3 ± 21.2

25.0 (0.0–50.0)

Ziv-aflibercept

33

30.6 ± 19.2

33.3 (16.7–50.0)

  

p < 0.001 (H3 = 34.594; Z = 4.335 and r = 0.75)

Aflib > (Beva = Rani = Ziv)

  1. Note: p → Kruskal–Wallis test
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us